ALK inhibitors in the treatment of advanced NSCLC.

Détails

ID Serval
serval:BIB_E334AE46A401
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
ALK inhibitors in the treatment of advanced NSCLC.
Périodique
Cancer Treatment Reviews
Auteur(s)
Gridelli C., Peters S., Sgambato A., Casaluce F., Adjei A.A., Ciardiello F.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
2014
Volume
40
Numéro
2
Pages
300-306
Langue
anglais
Notes
Publication types: Journal Article ; ReviewPublication Status: ppublishDocument Type: Review
Résumé
Pharmacologic agents that target protein products of oncogenes in tumors are playing an increasing clinical role in the treatment of cancer. Currently, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. Subsequently other genetic abnormalities with "driver" characteristics - implying transforming and tumor maintenance capabilities have been extensively reported in several small distinct subsets of NSCLC. Among these rare genetic changes, anaplastic lymphoma kinase (ALK) gene rearrangements, most often consisting in a chromosome 2 inversion leading to a fusion with the echinoderm microtubule-associated protein like 4 (EML4) gene, results in the abnormal expression and activation of this tyrosine kinase in the cytoplasm of cancer cells. This rearrangement occurs in 2-5% of NSCLC, predominantly in young (50 years or younger), never- or former-smokers with adenocarcinoma. This aberration most commonly occurs a independently of EGFR and KRAS gene mutations. A fluorescent in situ hybridization assay was approved by the US Food and Drug Administration (FDA) as the standard method for the detection of ALK gene rearrangement in clinical practice and is considered the gold standard. Crizotinib, a first-in-class dual ALK and c-MET inhibitor, has been shown to be particularly effective against ALK positive NSCLC, showing dramatic and prolonged responses with low toxicity, predominantly restricted to the gastro-intestinal and visual systems, and generally self-limiting or easily managed. However, resistance to crizotinib inevitably emerges. The molecular mechanisms of resistance are currently under investigation, as are therapeutic approaches including crizotinib-based combination therapy and novel agents such as Hsp90 inhibitors. This review aims to present the current knowledge on this fusion gene, the clinic-pathological profile of ALK rearranged NSCLC, and to review the existing literature on ALK inhibitors, focusing on their role in the treatment of NSCLC.
Mots-clé
Adenocarcinoma/drug therapy, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Chromosome Inversion, Chromosomes, Human, Pair 2/genetics, Drug Resistance, Neoplasm, Enzyme Activation, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Oncogene Proteins, Fusion/antagonists & inhibitors, Oncogene Proteins, Fusion/genetics, Protein Kinase Inhibitors/pharmacology, Protein Kinase Inhibitors/therapeutic use, Pyrazoles/pharmacology, Pyrazoles/therapeutic use, Pyridines/pharmacology, Pyridines/therapeutic use, Receptor Protein-Tyrosine Kinases/antagonists & inhibitors, Receptor Protein-Tyrosine Kinases/genetics
Pubmed
Web of science
Création de la notice
07/02/2014 19:12
Dernière modification de la notice
20/08/2019 17:07
Données d'usage